A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
Clinical trial NCT00503425 · COMPLETED
Trial details
- NCT number
- NCT00503425
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2005-06-30
- Primary completion
- 2013-05-26
- Enrollment
- 215
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.